AlphAIAlphAI — Financial news for AI agents
investing.comSEP 161 min read$TRAX

First Tracks Biotherapeutics stock rises on Guggenheim buy rating

First Tracks Biotherapeutics (TRAX) shares rose 3.8% after Guggenheim initiated coverage with a Buy rating and $100 price target, citing confidence in its anti-CD122 target and lead asset ANB033 for autoimmune diseases. Guggenheim analyst Yatin Suneja highlighted the company's unique position as the only publicly traded small-to-mid cap firm developing an anti-CD122 monoclonal antibody.

Original reporting
investing.com
Published Sep 16, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$TRAX
Bullish
high confidence
Mentioned
$TRAX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TRAXBullishMed
01

Why it matters

Analyst coverage adds credibility and may attract institutional interest.

02

Market read

New coverage can drive short‑term price action and influence sector sentiment.

03

What to watch

Potential competition from other IL‑15/CD122 programs and funding requirements.

Relevance 7/10Novelty 7/10Timing: today

Background

First Tracks Biotherapeutics focuses on anti‑CD122 monoclonal antibodies for autoimmune diseases.

Company-level read

Ticker impact

$TRAXBullishHigh confidence
Context

Guggenheim initiated coverage with a Buy rating and $100 price target, causing a 3.8% share rise.

Expected impact

Potential further rally toward the $100 target.

Evidence & confidence

Buy rating and price target provide a clear catalyst for traders.

Market effects

Sector

Highlights growing interest in anti‑CD122 therapeutics within biotech.

Regional

US biotech sector may see modest lift.

Global

Limited to niche immunology space.

Counterpoint

What could challenge this read

Rating could be premature; clinical data still early and target risk remains high.

Key entities

  • company
    First Tracks Biotherapeutics Inc

    Biotech firm developing anti‑CD122 therapy.

  • analyst_firm
    Guggenheim Partners

    Initiated coverage with a Buy rating.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 16
$TRAXHigh

Why is First Tracks Biotherapeutics stock rallying today?

First Tracks Biotherapeutics (TRAX) rose 4.5% after Guggenheim and UBS initiated coverage with Buy ratings and a $100 price target, citing potential in ANB033 for autoimmune diseases. The FDA granted Fast Track designation, and Phase 1b data is expected in Q4 2026. The Nasdaq and S&P 500 also gained 0.8% and 0.4%, respectively.

investing.com1 min
AUG 12
$TRAXMed

First Tracks Biotherapeutics, Inc. (TRAX): Results of Operations and Financial Condition

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2

SEC EDGAR 8-K5 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min
JUL 10
$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

rttnews.com6 min
JUN 3
$TRAXMedAI 8/10

Traxtion secures $86m investment to revitalise South Africa’s rail sector

Traxtion said it has completed an $86m equity capital raise to fund its long-term plan to revitalise South Africa’s rail sector. The round includes STANLIB Infrastructure Investments, Standard Bank and Harith InfraCo, via minority stakes. Traxtion said the equity closes funding for its R3.4bn rolling stock programme (46 locomotives, 920 wagons) and supports further refurbishment and expansion.

cbn.co.za4 min